Loading...
•
Mar 31
Y-mAbs Q1 2025 Earnings Report
Y-mAbs reported their first quarter 2025 financial results and recent corporate developments.
Key Takeaways
Y-mAbs reported a net loss of $5.2 million for the first quarter of 2025, an improvement from the $6.6 million net loss in the same period last year. Total revenues increased 5% year-over-year to $20.9 million, driven by a significant increase in Ex-U.S. DANYELZA revenue, partially offset by a decrease in U.S. DANYELZA revenue.
Total revenues for Q1 2025 were $20.9 million, a 5% increase compared to Q1 2024.
Net loss for Q1 2025 was $5.2 million, an improvement from a $6.6 million net loss in Q1 2024.
Ex-U.S. DANYELZA net product revenue increased by $6.7 million, while U.S. DANYELZA net product revenue decreased by $5.2 million year-over-year.
Cash and cash equivalents stood at $60.3 million as of March 31, 2025, expected to fund operations into 2027.
Y-mAbs
Y-mAbs
Y-mAbs Revenue by Segment
Y-mAbs Revenue by Geographic Location
Revenue by Segment
DANYELZA Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comEx-U.S. Revenue
CapyFin.com Forward Guidance
Management reiterated full-year 2025 guidance and provided revenue guidance for the second quarter of 2025.
Positive Outlook
- Anticipated Total Revenues for full year 2025 expected between $75 million and $90 million.
- Cash and Cash Equivalents anticipated to be sufficient to fund operations into 2027.
- Anticipated Total Annual Cash Investment expected to be between $25 million and $30 million for full year 2025.
- Business realignment expected to accelerate clinical development and optimize DANYELZA's commercial potential.
- Second quarter 2025 Total Revenue anticipated to be between $17 million and $19 million.
Challenges Ahead
- U.S. DANYELZA net product revenues decreased due to enrollments in clinical studies and market dynamics.
- Increased operating costs and expenses, partially offsetting revenue growth.
- Cash investment of $6.9 million in Q1 2025.
- Estimate of cash runway is based on assumptions that may prove inaccurate.
- Macroeconomic conditions and other external factors could impact actual results.